Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep-Oct;21(5):493-499.
doi: 10.1016/j.bjid.2017.03.010. Epub 2017 Apr 19.

In vitro susceptibility of methicillin-resistant Staphylococcus aureus isolates from skin and soft tissue infections to vancomycin, daptomycin, linezolid and tedizolid

Johanna Marcela Vanegas Múnera  1 , Ana María Ocampo Ríos  1 , Daniela Montoya Urrego  1 , Judy Natalia Jiménez Quiceno  2
Affiliations

In vitro susceptibility of methicillin-resistant Staphylococcus aureus isolates from skin and soft tissue infections to vancomycin, daptomycin, linezolid and tedizolid

Johanna Marcela Vanegas Múnera et al. Braz J Infect Dis. 2017 Sep-Oct.

Abstract

Introduction: Treatment of multidrug-resistant Gram-positive infections caused by Staphylococcus aureus remains as a clinical challenge due to emergence of new resistance mechanisms. Tedizolid is a next-generation oxazolidinone, recently approved for skin and soft tissues infections. We conducted a study to determine in vitro susceptibility to vancomycin, daptomycin, linezolid and tedizolid in MRSA clinical isolates from adult patients with skin and soft tissue infections.

Material and methods: Methicillin-resistant S. aureus isolates were collected in three tertiary-care hospitals of Medellin, Colombia, from February 2008 to June 2010 as part of a previous study. Clinical characteristics were assessed by medical records and MIC values were determined by Epsilometer test. Genotypic analysis included spa typing, MLST, and SCCmec typing.

Results: A total of 150 MRSA isolates were evaluated and tedizolid MIC values obtained showed higher in vitro activity than other antimicrobials, with MIC values ranging from 0.13μg/mL to 0.75μg/mL and lower values of MIC50 and MIC90 (0.38μg/mL and 0.5μg/mL). In contrast, vancomycin and linezolid had higher MIC values, which ranged from 0.5μg/mL to 2.0μg/mL and from 0.38μg/mL to 4.0μg/mL, respectively. Tedizolid MICs were 2- to 5-fold lower than those of linezolid. Clinical characteristics showed high previous antimicrobial use and hospitalization history. The majority of the strains belong to the CC8 harboring the SCCmec IVc and were associated with the spa t1610 (29.33%, n=44).

Conclusion: In vitro effectiveness of tedizolid was superior for isolates from skin and soft tissue infections in comparison with the other antibiotics evaluated. The above added to its less toxicity, good bioavailability, daily dose and unnecessity of dosage adjustment, make tedizolid in a promising alternative for the treatment of infections caused by MRSA.

Keywords: Daptomycin; Linezolid; MRSA; Skin and soft tissues infections; Tedizolid; Vancomycin.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
SCCmec types according to tedizolid MIC values in MRSA isolates.
Fig. 2
Fig. 2
Comparison between tedizolid, daptomycin, vancomycin and linezolid MIC in MRSA isolates.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. DeLeo F.R., Diep B.A., Otto M. Host defense and pathogenesis in Staphylococcus aureus infections. Infect Dis Clin N Am. 2009;23:17–34. - PMC - PubMed
    1. Aires de Sousa M., de Lencastre H. Bridges from hospitals to the laboratory: genetic portraits of methicillin-resistant Staphylococcus aureus clones. FEMS Immunol Med Microbiol. 2004;40:101–111. - PubMed
    1. Gordon R.J., Lowy F.D. Pathogenesis of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis. 2008;46(Suppl. 5):S350–S359. - PMC - PubMed
    1. Lowy F.D. Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Invest. 2003;111:1265–1273. - PMC - PubMed
    1. Ruef C. Epidemiology and clinical impact of glycopeptide resistance in Staphylococcus aureus. Infection. 2004;32:315–327. - PubMed

MeSH terms